GOLDENWELL BIOTECH, INC. reported fiscal 2025 results showing sharply lower revenue and a wider net loss versus the prior year. Revenue fell to $55 for FY 2025 from $139 in FY 2024, while the company recorded a net loss of $296471 and diluted loss per share of $(2.99).
Financial Highlights
- Revenue was $55 for FY 2025, compared with $139 in FY 2024; YoY change (60.4%).
- Net income: Net loss $296,471 for FY 2025, compared with net loss $131,498 in FY 2024 (worsened).
- Diluted EPS: $(2.99) per share for FY 2025 (basic and diluted), versus $(1.33) per share in FY 2024.
Business Highlights
- Revenue Trend: The company generated nominal revenues ($55 in 2025 vs $139 in 2024), indicating limited commercial traction and declining sales.
- Operational Focus: GOLDENWELL BIOTECH is an early-stage nutraceuticals business planning to increase product sales over the next 12 months and expand commercial activities.
- Manufacturing Milestone Plan: Management plans to construct manufacturing facilities within approximately one year, estimating about $5 million plus non-specialized equipment and training.
- Liquidity: Management expects current cash to support operations through December 31, 2026, and intends to seek equity or private placements to fund growth.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.